Literature DB >> 10428468

N-acylphosphatidylethanolamine-hydrolysing phospholipase D lacks the ability to transphosphatidylate.

G Petersen1, H S Hansen.   

Abstract

The N-acylphosphatidylethanolamine-hydrolysing phospholipase D (NAPE-PLD) generates N-acylethanolamines, including N-arachidonoyl-ethanolamine (anandamide), that may be neuroprotective and analgesic. The properties of NAPE-PLD from rat heart and brain microsomes are investigated and compared to those of other PLDs. NAPE-PLD is inhibited by the fatty acid aminohydrolase inhibitor MAFP in high concentrations (> or = 100 microM) while PMSF in high concentrations (10 mM) tends to stabilise NAPE-PLD activity. Oleate inhibits NAPE-PLD but the enzyme is not affected by PIP2, alpha-synuclein or mastoparan. Furthermore, it is for the first time reported that NAPE-PLD is not capable of catalysing a transphosphatidylation reaction like most other known PLDs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10428468     DOI: 10.1016/s0014-5793(99)00861-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

Review 1.  The endocannabinoid system: a general view and latest additions.

Authors:  Luciano De Petrocellis; Maria Grazia Cascio; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

Review 2.  Phospholipase D: enzymology, functionality, and chemical modulation.

Authors:  Paige E Selvy; Robert R Lavieri; Craig W Lindsley; H Alex Brown
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

3.  Isolevuglandin-modified phosphatidylethanolamine is metabolized by NAPE-hydrolyzing phospholipase D.

Authors:  Lilu Guo; Stephen D Gragg; Zhongyi Chen; Yongqin Zhang; Venkataraman Amarnath; Sean S Davies
Journal:  J Lipid Res       Date:  2013-09-09       Impact factor: 5.922

4.  Mammalian cells stably overexpressing N-acylphosphatidylethanolamine-hydrolysing phospholipase D exhibit significantly decreased levels of N-acylphosphatidylethanolamines.

Authors:  Yasuo Okamoto; Jun Morishita; Jun Wang; Patricia C Schmid; Randy J Krebsbach; Harald H O Schmid; Natsuo Ueda
Journal:  Biochem J       Date:  2005-07-01       Impact factor: 3.857

Review 5.  Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases.

Authors:  Mario van der Stelt; Henrik H Hansen; Wouter B Veldhuis; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Johannes F G Vliegenthart; Harald S Hansen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

6.  Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D.

Authors:  Yong-Xin Sun; Kazuhito Tsuboi; Yasuo Okamoto; Takeharu Tonai; Makoto Murakami; Ichiro Kudo; Natsuo Ueda
Journal:  Biochem J       Date:  2004-06-15       Impact factor: 3.857

7.  The Concise Guide to PHARMACOLOGY 2013/14: enzymes.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

8.  Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes.

Authors:  Sarah A Scott; Cierra T Spencer; Matthew C O'Reilly; Kyle A Brown; Robert R Lavieri; Chul-Hee Cho; Dai-Il Jung; Richard C Larock; H Alex Brown; Craig W Lindsley
Journal:  ACS Chem Biol       Date:  2014-11-19       Impact factor: 5.100

9.  Selective measurement of NAPE-PLD activity via a PLA1/2-resistant fluorogenic N-acyl-phosphatidylethanolamine analog.

Authors:  Jonah E Zarrow; Jianhua Tian; Brendan Dutter; Kwangho Kim; Amanda C Doran; Gary A Sulikowski; Sean S Davies
Journal:  J Lipid Res       Date:  2021-11-26       Impact factor: 5.922

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.